Publication: Reply to: "The predictive value of significant fibrosis for metabolic disturbances in patients with NAFLD".
No Thumbnail Available
Identifiers
Date
2021
Authors
Ampuero, Javier
Gallego-Duran, Rocio
Romero-Gomez, Manuel
Advisors
Journal Title
Journal ISSN
Volume Title
Publisher
Elsevier BV
Abstract
Mao et al. suggest the modification of several parameters employed in the paper for the diagnosis of the dysmetabolic-related outcomes. First, these authors propose using glucose intolerance tests instead of a diagnosis of type 2 diabetes mellitus as an outcome measure . We fully agree with the correspondents about the usefulness of the early detection of glucose intolerance due to the capacity to prevent further events in patients at risk of progressing to diabetes mellitus . However, these tests, such as oral glucose tolerance test , are not suitable for a wide screening of patients because they are time -consuming (2 hours duration) and not cost -effective in this scenario.3 Further, these tests are typically carried out in dedicated units, such as Endocrinology units
Description
MeSH Terms
Glucose Intolerance
Diabetes Mellitus, Type 2
Glucose Tolerance Test
Early Diagnosis
Outcome Assessment, Health Care
Diabetes Mellitus, Type 2
Glucose Tolerance Test
Early Diagnosis
Outcome Assessment, Health Care
DeCS Terms
Intolerancia a la glucosa
Diabetes Mellitus
Prueba de Tolerancia a la glucosa
Monoaminooxidasa
Endocrinología
Diabetes Mellitus
Prueba de Tolerancia a la glucosa
Monoaminooxidasa
Endocrinología
CIE Terms
Keywords
Fibrosis, Humans, Liver Cirrhosis, Non-alcoholic Fatty Liver Disease
Citation
Ampuero J, Gallego-Durán R, Romero-Gómez M. Reply to: "The predictive value of significant fibrosis for metabolic disturbances in patients with NAFLD". J Hepatol. 2021 Apr;74(4):971-972.






